Aurora M. Fontainhas

Array ( [id] => 18582941 [patent_doc_number] => 20230265199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLAMMATION [patent_app_type] => utility [patent_app_number] => 18/188707 [patent_app_country] => US [patent_app_date] => 2023-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18188707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581621 [patent_doc_number] => 20230263873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS [patent_app_type] => utility [patent_app_number] => 18/178055 [patent_app_country] => US [patent_app_date] => 2023-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18496066 [patent_doc_number] => 20230218603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => PSILOCYBIN COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/114381 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18114381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492659 [patent_doc_number] => 12534522 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Anti-complement factor C1q antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/110574 [patent_app_country] => US [patent_app_date] => 2023-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 30892 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18110574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709218 [patent_doc_number] => 20230331830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/099671 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18099671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628239 [patent_doc_number] => 20230287093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/155230 [patent_app_country] => US [patent_app_date] => 2023-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18155230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418651 [patent_doc_number] => 20230173110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => NON-HUMAN MAMMAL MODEL OF HUMAN DEGENERATIVE DISORDER, USES THEREOF, AND METHOD OF TREATING HUMAN DEGENERATIVE DISORDER [patent_app_type] => utility [patent_app_number] => 18/096718 [patent_app_country] => US [patent_app_date] => 2023-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18096718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511421 [patent_doc_number] => 20230227571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => ANTI-C5 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/153720 [patent_app_country] => US [patent_app_date] => 2023-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18153720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19922992 [patent_doc_number] => 12297263 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Humanized anti-Tau(PS422) antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 18/091056 [patent_app_country] => US [patent_app_date] => 2022-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 35773 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18091056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18568325 [patent_doc_number] => 20230258661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => METHODS AND SYSTEMS OF DIAGNOSING BRAIN INJURY [patent_app_type] => utility [patent_app_number] => 18/147420 [patent_app_country] => US [patent_app_date] => 2022-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18147420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725864 [patent_doc_number] => 20230340092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => Collagen Type XVIII Assay [patent_app_type] => utility [patent_app_number] => 18/145767 [patent_app_country] => US [patent_app_date] => 2022-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484958 [patent_doc_number] => 20230212273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => CHIMERIC ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES [patent_app_type] => utility [patent_app_number] => 18/066469 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18066469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18737983 [patent_doc_number] => 20230346886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => NON-LEAKING OR MINIMALLY-LEAKING CHOROIDAL OR RETINAL REVASCULARIZATION [patent_app_type] => utility [patent_app_number] => 18/076786 [patent_app_country] => US [patent_app_date] => 2022-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18076786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808648 [patent_doc_number] => 20230382982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => MUTATIONS THAT DRIVE VH4 ANTIBODY AUTOREACTIVITY [patent_app_type] => utility [patent_app_number] => 18/058965 [patent_app_country] => US [patent_app_date] => 2022-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18265626 [patent_doc_number] => 20230086868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/058425 [patent_app_country] => US [patent_app_date] => 2022-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675111 [patent_doc_number] => 20230312693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => Agents, Uses and Methods for the Treatment of Synucleinopathy [patent_app_type] => utility [patent_app_number] => 17/992403 [patent_app_country] => US [patent_app_date] => 2022-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17992403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961639 [patent_doc_number] => 12331123 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Agent, uses and methods for treatment [patent_app_type] => utility [patent_app_number] => 18/057104 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 42 [patent_no_of_words] => 24829 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497435 [patent_doc_number] => 20230220070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => ANTI-HUMAN NR1 ANTIBODY DERIVATIVE [patent_app_type] => utility [patent_app_number] => 18/056635 [patent_app_country] => US [patent_app_date] => 2022-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 487 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725863 [patent_doc_number] => 20230340091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHIES AND NEUROINFLAMMATION [patent_app_type] => utility [patent_app_number] => 18/054457 [patent_app_country] => US [patent_app_date] => 2022-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656212 [patent_doc_number] => 20230302096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => AGENTS DIRECTED AGAINST A CIS RGMA/NEOGENIN INTERACTION OR LIPID RAFTS AND USE OF THE SAME IN METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 18/047129 [patent_app_country] => US [patent_app_date] => 2022-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047129 [rel_patent_id] =>[rel_patent_doc_number] =>)